pfizer glp 1 news Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP-1 race Pfizer targets obesity with new

Pharmacovigilance analyses identified disproportionate reporting signals for dyspnoea and asthma-like events, particularly with exenatide, using the reporting odds ratio (ROR 2.14, 95% CI 1.882.43

37, 225e8

If you are interested in semaglutide weight loss in Houma, Wegovy might be the right choice for you

For patients & payers: A step toward lower costs and broader access to proven obesity treatments For Teva Pharmaceuticals: A strategic move into one of the fastest-growing segments in global pharma For Novo Nordisk: Limited short-term impact, but mounting competitive pressure as generics gain ground This development could reshape affordability, accessibility, and competition in obesity care signaling the beginning of a new chapter for patients and healthcare systems worldwide